GlycoMimetics

GlycoMimetics is a publicly traded biotechnology company headquartered in Rockville, Maryland. The company employs 42 people and generates approximately $3 million in annual revenue. GlycoMimetics is a late clinical-stage biotechnology company focused on discovering and developing innovative treatments for patients with cancer and inflammatory diseases. GlycoMimetics specializes in glycomimetics, small molecule drugs that manipulate carbohydrate-mediated cell recognition processes. These therapies target a wide range of diseases, including acute myeloid leukemia and sickle cell disease. The company leverages its proprietary chemistry platform and a deep understanding of carbohydrate biology to design and develop groundbreaking drug candidates. GlycoMimetics is dedicated to advancing its research and clinical candidates through late-stage development, ultimately aiming to deliver transformative treatments to patients in need. GlycoMimetics differentiates itself through its proprietary chemistry platform and expertise in glycobiology. The company's focus on understanding the intricate role of carbohydrates in disease processes allows for the development of highly targeted and potentially more effective therapies. By harnessing its development and commercial expertise, GlycoMimetics strives to bring its promising drug candidates to market and ultimately improve patient outcomes. Investors can find more information about GlycoMimetics and its work on the NASDAQ stock exchange under the symbol GLYC.